Newsletter sign-up

RESI Conference - San Francisco
Tuesday, 9 January 2018

We are looking forward to the RESI conference, where we will present our exciting growth opportunity to investors and other interested parties

Biologics Symposium - Copenhagen
Tuesday, 16 January 2018

As an active member of the biologics and regenerative medicine community, we are looking forward to the discussions at this meeting

Biotech & Money - London
Monday, 5 February 2018

Our CEO, Graeme Brookes, is an invited panel member for the CEO Panel discussion during the meeting

Bio-Europe Spring - Amsterdam
Monday, 12 February 2018

We look forward to discussing our unique investment opportunity at this key event

DK Bio - Boston
Tuesday, 10 April 2018

Once again, we look forward to being part of continuing to build and strengthen Danish-US life science connections

SAWC - Charlotte
Wednesday, 25 April 2018

We look forward to seeing friends and contacts at the SAWC

EWMA - Krakow
Wednesday, 9 May 2018

We will attend the whole conference and will also present at the ‘New Technologies in Wound Care’ Symposium in the Budapest Room at the congress centre on Thursday, May 10th 16.00 - 17.00

< Back to overview

Study Shows Effectiveness of LeucoPatch in Healing Diabetic Foot Ulcers

by Rasmus Lundquist

A newly published study using LeucoPatch, a unique active wound therapy, developed by Reapplix ApS (Reapplix), has been published showing that LeucoPatch was highly effective in healing diabetic foot ulcers. The multicentre study, which is published in The Journal of Wound Care, tested LeucoPatch in healing diabetic foot ulcers in 44 hard to heal patients. Only patients with ulcers that had persisted for at least eight weeks and had no or low wound area reduction, despite the use of conventional treatments, were included. The researchers found that in patients with an ulcer duration of less than six months, 73% of ulcers were healed when using LeucoPatch. In addition, the study found that no serious adverse events were related to the use of LeucoPatch. Based on this positive outcome, Reapplix is currently conducting a large scale randomized controlled trial of 250 patients in 28 centres across Europe and expects to report the data from this in early 2017. Diabetic foot ulcers are a major complication in diabetes, with up to 25% of patients being affected. Also, diabetic foot ulcers precede 80% of all lower leg amputations. At the same time, they are particularly difficult to manage, requiring intensive treatment.

Commenting on the news, Rasmus Lundquist, Chief Scientific Officer at Reapplix said: “Diabetic foot ulcers are a significant problem, and with the increasing levels of diabetes in society are set to become an even greater problem. As around 40% cannot be healed within one year using optimal current wound care methods, they have a significant impact on quality of life and are extremely costly. However, this new data shows that LeucoPatch is effective in treating diabetic foot ulcers, and there is an opportunity to make a significant difference to patient outcomes and overall healthcare costs.”

Graeme Brookes, Chief Executive Officer at Reapplix, added: “The publication of this study is excellent news for Reapplix. The data is strong and compelling and we can leverage this as we build out our commercialisation efforts in Europe and continue to develop our market access plans for the USA.”

Top